Login to Your Account



Anti-Cholesterol PCSK9 Race: Regeneron, Sanofi Lead Dogs

By Randy Osborne
Staff Writer

Tuesday, November 6, 2012
With a year's worth of progress on the would-be competition targeting cholesterol by way of a new mechanism, Regeneron Pharmaceuticals Inc. and partner Sanofi SA set forth on another Phase III trial – this time measuring cardiovascular (CV) outcomes – with SAR236553/REGN727.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription